Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

NCT06611813 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

HR+/HER2- Breast Cancer

Interventions

DRUG: Neoadjuvant Chemotherapy in Combination with Toripalimab
DRUG: HR+ HER2 breast cancer

Sponsor

First Affiliated Hospital of Zhejiang University